(Updates with company statement in third paragraph.)
Jan. 23 (Bloomberg) -- Medicines Co. and Fresenius’s APP Pharmaceuticals Inc. settled litigation over patents for the Angiomax anticoagulant drug, with Medicines agreeing to pay $30 million to license some APP drugs.
Medicines Co., based in Parsippany, New Jersey, sued Schaumburg, Illinois-based APP in October 2009 IN Wilmington, Delaware, federal court alleging patent infringement for plans to market a generic copy of Angiomax. APP announced the settlement today.
“The settlement agreement includes a license by The Medicines Co. to APP” to sell generic Angiomax in the U.S. starting May 1, 2019, Medicines said in a statement.
Medicines will pay APP $30 million for a non-exclusive license “to sell 10 specified generic products” to hospitals and suppliers until Jan. 22, 2022, according to a Medicines filing with the U.S. Securities and Exchange Commission.
The case is The Medicines Co. v. APP Pharmaceuticals, 09- CV-00752, U.S. District Court, District of Delaware (Wilmington).
--Editors: Andrew Dunn, Peter Blumberg
To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at firstname.lastname@example.org.
To contact the editor responsible for this story: Michael Hytha at email@example.com.